In 2019, approximately 40% of oncology patients in the United States were eligible for treatment with immune checkpoint inhibitors (ICIs). Furthermore, it is estimated that one in seven patients who ...
An interview with Dr. Bryan Schneider from the University of Michigan Health System and Dr. Kathryn Bollin from Scripps MD Anderson Cancer Center, co-chairs of the Management of Immune-Related Adverse ...
There has been a lot of conversation over the years about risk management; this has included its importance and how to do it. Unfortunately, all this conversation has taken place separately, and there ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results